The American market-focused Baddi facility of Glenmark Pharmaceuticals Ltd. has been identified as having quality control and operational flaws. After completing its inspection at the non-sterile finished drugmaking facility USFDA issued a Form 483 with six observations.
For the fiscal year ending December 31, 2022, pharmaceutical company Sanofi India declared a one-time special interim dividend of ₹193 per equity share. The company has released its second quarterly report for the year, showing a sequential and annual fall in both net profit and revenue.
Due to ongoing pricing pressure, the absence of significant generic product releases, and heightened regulatory scrutiny, the revenues from the US market have expanded at a relatively slow rate.
The production linked incentive (PLI) scheme for the creation of vitamin B1 by chemical synthesis has been extended by the Department of Pharmaceuticals (DoP) to qualifying API producers throughout the nation.
The government intends to rationalize trade margins on non-scheduled medications in the near future. The pharmaceutical sector and government organizations have met extensively to discuss trade margin optimization in order to ensure affordable access to quality healthcare.
Sun Pharmaceutical Industries said that it has broadened the scope of its collaboration with Cassiopea on an acne medicine. In order to expand the territory, it has signed addendum to the licence and supply agreements for WINLEVI (clascoterone) cream 1%.
The largest manufacturer of vaccines in the
world, Serum Institute of India (SII), has
started talking with potential collaborators
about creating a vaccine for monkeypox. The
CEO of SII reported that he was in discussions
with possible vaccine-development partners.